Asset Details
Do you wish to reserve the book?
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
Do you wish to request the book?
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
2006
Overview
The infusion of bone marrow–derived progenitor cells into the infarct-related coronary artery after an acute myocardial infarction was associated with an absolute increase in the ejection fraction of 5.5%. Determining whether this modest improvement in ventricular function will translate into a long-term clinical benefit will require larger trials with longer follow-up.
The infusion of bone marrow–derived progenitor cells into the infarct-related coronary artery after an acute myocardial infarction was associated with an absolute increase in the ejection fraction of 5.5%.
Prompt reperfusion of the infarct-related coronary artery has considerably improved the clinical outcome in patients with acute myocardial infarction.
1
Although contemporary reperfusion strategies using stent implantation and aggressive inhibition of platelet aggregation have been shown to increase myocardial salvage,
2
improvements in global left ventricular function are rather modest, despite the use of optimal reperfusion therapy.
3
,
4
Heart failure that develops after infarction remains a major cause of morbidity and mortality.
5
,
6
Experimental studies suggested that intravascular or intramyocardial administration of progenitor cells derived from bone marrow (BMC) or blood may contribute to functional regeneration of infarcted myocardium and enhance neovascularization . . .
Publisher
Massachusetts Medical Society
